| Literature DB >> 33109175 |
Ruben D Vromans1, Steffen C Pauws2,3, Nadine Bol2, Lonneke V van de Poll-Franse4,5,6, Emiel J Krahmer2.
Abstract
BACKGROUND: The increased availability of patient reported outcome data makes it feasible to provide patients tailored risk information of cancer treatment side effects. However, it is unclear how such information influences patients' risk interpretations compared to generic population-based risks, and which message format should be used to communicate such individualized statistics.Entities:
Keywords: Cancer; Message format; Patient information; Personalization; Risk communication; Shared decision-making; Tailoring; Treatment side effects
Mesh:
Substances:
Year: 2020 PMID: 33109175 PMCID: PMC7590680 DOI: 10.1186/s12911-020-01296-7
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Verbal descriptors of side effects risks and their corresponding numerical probabilities as recommended by the European Commission [22]
| Verbal descriptor | Corresponding numerical frequency interval |
|---|---|
| Very common | May affect more than 1 in 10 people (≥ 1/10) |
| Common | May affect up to 1 in 10 people (≥ 1/100 to < 1/10) |
| Uncommon | May affect up to 1 in 100 people (≥ 1/1000 to < 1/100) |
| Rare | May affect up to 1 in 1,000 people (≥ 1/10,000 to < 1/1000) |
| Very rare | May affect up to 1 in 10,000 people (< 1/10,000) |
| Not known | Frequency cannot be estimated from the available data |
Development and structure of the risk information about the likelihood of occurrence for each experimental condition
| Verbal-only condition | Verbal and numerical combined condition | |||
|---|---|---|---|---|
| Generic | Tailored | Generic | Tailored | |
| Low probability rate | This side effect is common | This side effect is common in [gender] like you, aged between [age group] years with advanced colon cancer | This side effect is common (occurs in 10 out of 100 people) | This side effect is common (occurs in 10 out of 100 [gender] like you, aged between [age group] with advanced colon cancer) |
| High probability rate | This side effect is very common | This side effect is very common in [gender] like you, aged between [age group] with advanced colon cancer | This side effect is very common (occurs in 40 out of 100 people) | This side effect is very common (occurs in 40 out of 100 [gender] like you, aged between [age group] with advanced colon cancer) |
The risk information was presented in Dutch to the participants
Fig. 1Flowchart of the data collection process
Participant characteristics by message format condition
| Verbal-only ( | Verbal and numerical combined ( | ||||
|---|---|---|---|---|---|
| % | % | ||||
| Gender | |||||
| Female | 45 | 35 | 46 | 36 | |
| Male | 24 | 65 | 26 | 64 | .869 |
| Age at time of experiment, mean (SD) | 57.72 (7.29) | 56.83 (7.50) | .469 | ||
| < 50 years | 8 | 11 | 13 | 18 | |
| 50–65 years | 44 | 64 | 49 | 68 | |
| > 65 years | 17 | 25 | 10 | 14 | .201 |
| Education | |||||
| Primary school | 8 | 11 | 12 | 17 | |
| Secondary school | 17 | 25 | 24 | 33 | |
| College/University | 44 | 64 | 36 | 50 | .255 |
| Tumor | |||||
| Breast | 22 | 32 | 22 | 31 | |
| Hematologicala | 13 | 19 | 8 | 12 | |
| Urologicalb | 10 | 15 | 13 | 18 | |
| Gynecologicalc | 7 | 10 | 10 | 14 | |
| Head and neck | 4 | 6 | 6 | 8 | |
| Lung | 2 | 3 | 4 | 5 | |
| Skin | 3 | 4 | 2 | 3 | |
| Gastroenterologicald | 3 | 4 | 2 | 3 | |
| Othere | 3 | 4 | 4 | 5 | |
| Unknown | 2 | 3 | 1 | 1 | .912 |
| Years since diagnosis, mean (SD) | 6.48 (6.89) | 5.01 (4.22) | .133 | ||
| 0–5 years | 43 | 62 | 52 | 72 | |
| 6–10 years | 12 | 17 | 13 | 18 | |
| 11–15 years | 8 | 12 | 5 | 7 | |
| > 15 years | 6 | 9 | 2 | 3 | .318 |
| Treatment(s) | |||||
| Surgery | 48 | 70 | 48 | 67 | .712 |
| Radiotherapy | 40 | 58 | 35 | 49 | .266 |
| Chemotherapy | 40 | 58 | 37 | 51 | .433 |
| Immunotherapy | 13 | 19 | 11 | 15 | .574 |
| Hormone therapy | 18 | 26 | 24 | 33 | .347 |
| Other | 16 | 23 | 13 | 18 | .451 |
| Prior experience side effects | |||||
| Fatigue | 55 | 80 | 49 | 68 | .116 |
| Neuropathy | 29 | 42 | 26 | 36 | .471 |
| Smell and taste changes | 30 | 44 | 27 | 38 | .470 |
| Diarrhea | 14 | 20 | 11 | 15 | .436 |
| None of the above | 7 | 10 | 9 | 13 | .659 |
| Subjective numeracy, mean (SD)f | 4.51 (0.81) | 4.64 (0.86) | .384 | ||
aLymphoma, Leukemia, Multiple myeloma
bProstate, bladder
cUterus, cervix, ovary
dEsophageal, anus, GIST, gall bladder, but excluding colorectal cancer
eBrain, renal cell, undifferentiated pleomorphic sarcoma, neuroendocrine tumor
fα = .82; SD standard deviation
Participants’ mean scores (with standard deviations within parentheses) on the primary and secondary outcome measures as a function of tailoring (tailored vs. generic risks) and message format (verbal-only vs. verbal and numerical combined) for low probability rate risks
| Measures | Verbal-only “common” | Verbal and numerical combined “common, 10 out of 100” | ||||
|---|---|---|---|---|---|---|
| Generic | Tailored | Total | Generic | Tailored | Total | |
| Estimation of probability1 (in %) | 64.8 (20.1) | 70.1 (19.6)a** | 67.5 (19.8) | 34.3 (29.9) | 32.9 (30.8) | 33.6 (30.4)c*** |
| Accuracy of estimation of probability2 (in %) | 54.8 (20.1) | 60.1 (19.6)a*** | 57.5 (19.9) | 24.9 (29.4) | 23.7 (30.2) | 24.3 (29.7)c*** |
| Perceived likelihood of occurrence3 | 4.41 (1.09) | 4.46 (1.01) | 4.49 (1.05) | 3.25 (1.52) | 3.23 (1.57) | 3.24 (1.55)c*** |
| Perceived personal relevance4 | 3.16 (0.74) | 3.46 (0.81)a*** | 3.34 (0.78) | 3.19 (0.97) | 3.40 (0.91)b*** | 3.30 (0.94) |
| Perceived uncertainty5 | 2.90 (1.19) | 2.59 (1.19)a* | 2.75 (1.19) | 3.13 (1.50) | 3.31 (1.47) | 3.18 (1.49) |
1“What do you think is the probability you will experience this side effect” (percentage between 0 and 100%)
2The absolute difference between the actual risk of each side effect occurring and each participant’s estimated risk (scores closer to zero are more accurate)
3“How likely is it that you will experience this side effect?” (1 = not likely at all, 6 = very likely)
4“The risk information about the side effect was made personally for me” and “The way how the risk information was being presented was relevant to me” (1 = strongly disagree, 5 = strongly agree, α = .87)
5“How uncertain do you think is this likelihood of experiencing this side effect after chemotherapy?” (1 = not at all, 6 = extremely)
aMean differs significantly compared to generic risk within verbal-only risk condition
bMean differs significantly compared to generic risk within verbal and numerical combined condition
cMean differs significantly compared to total verbal-only risk; *p < .01, **p = .001, ***p < .001
Participants’ mean scores (with standard deviations within parentheses) on the primary and secondary outcome measures as a function of tailoring (tailored vs. generic risks) and message format (verbal-only vs. verbal and numerical combined) for high probability rate risks
| Measures | Verbal-only “very common” | Verbal and numerical combined “very common, 40 out of 100” | ||||
|---|---|---|---|---|---|---|
| Generic | Tailored | Total | Generic | Tailored | Total | |
| Estimation of probability (in %) | 71.0 (21.1) | 78.9 (18.1)a** | 74.9 (19.1) | 53.5 (22.3) | 54.0 (21.9) | 53.7 (22.1)c*** |
| Accuracy of estimation of probability (in %) | 32.1 (19.5) | 39.6 (16.7) a*** | 35.8 (18.1) | 17.4 (19.3) | 17.9 (18.7) | 17.7 (19.0)c*** |
| Perceived likelihood of occurrence | 4.73 (1.07) | 5.02 (0.98) | 4.87 (1.03) | 4.23 (1.22) | 4.28 (1.21) | 4.26 (1.22)c*** |
| Perceived personal relevance | 3.16 (0.74) | 3.47 (0.80) a*** | 3.39 (0.77) | 3.34 (0.89) | 3.47 (0.86) b*** | 3.40 (0.88) |
| Perceived uncertainty | 2.55 (1.30) | 2.41 (1.37)a* | 2.48 (1.34) | 2.73 (1.20) | 2.91 (1.36) | 2.82 (1.28) |
aMean differs significantly compared to generic risk within verbal-only risk condition
bMean differs significantly compared to generic risk within verbal and numerical combined condition
cMean differs significantly compared to total verbal-only risk; *p < .01, **p = .001, ***p < .001
Fig. 2Comparisons of distribution of estimations of probabilities between verbal-only (red) and verbal and numerical combined (blue) message formats for a low probability tailored risks and b low probability generic risks, and for c high probability tailored risks and d high probability generic risks. The dotted lines represent the average estimated risks